与马斯克技术路线不同？亚辉龙股价“精准”异动

Core Viewpoint - The company, Aihuilong, has signed a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd. to jointly develop brain-computer interface products and enhance diagnostic technology in central nervous diseases [1] Group 1: Strategic Cooperation - The agreement aims to integrate brain-computer interface technology with clinical and market resources for product development and market expansion [1] - Aihuilong currently holds a 4% indirect stake in Brain Machine Starlink [1] Group 2: Product Development and Status - Brain Machine Starlink, established in September 2025, focuses on comprehensive diagnosis, treatment, and rehabilitation of brain diseases [1] - The company is developing non-invasive products such as EEG analysis devices and vagus nerve stimulators, which are still in early research or preclinical stages [2] - The vagus nerve stimulator is in the registration preparation phase for Class II medical device certification [2] Group 3: Regulatory and Market Response - The Shanghai Stock Exchange has issued an inquiry requiring Aihuilong to provide additional details about the technical routes, product types, and commercialization status of Brain Machine Starlink [3] - Aihuilong is expected to disclose the feasibility of market promotion and the timeline for future agreements based on product development progress [3] Group 4: Financial Performance - Aihuilong reported a significant decline in revenue and net profit for the first three quarters of 2025, with revenues down 7.69% and net profit down 72% [4] - The company has a cash balance of 465 million yuan [4] - The stock price increased by 6.52% on the day of the announcement, with trading volume up 299% compared to the previous day [4]